Yeah, this company is completely under the radar today -- they have done virtually no PR in the US, but I don't blame them as until yesterday they didn't really have anything more than prospects. They aren't a typical OTC company .. they don't hope to flaunt their technology to drive up the stock price.
However with the PPA approved in SoCal, and the next steps that will certainly attract attention (building plans), I expect that they will try to promote themselves in the media a fair bit in the coming months. That, together with concrete announcements about their business model could spark a lot of interest in the stock.
This is ground floor pricing IMO... but they still have a lot to prove with their revenue model, so I think it may be as much as a year or more before this stock does any sort of interesting volume and the ADRs climb above $2-3.
Still, if you believe in the technology, and the ability for the current management team to promote it and execute the business plan, then I think it's a great long-term investment (with zero liquidity in the short term).
Tyk
